Skip to search formSkip to main contentSkip to account menu

otelixizumab

Known as: ChAglyCD3, Immunoglobulin G1, Anti-(Human CD3 (Antigen)) (Human-Rat Monoclonal Heavy Chain), Disulfide with Human-Rat Monoclonal lambda-Chain, Dimer 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Antibodies, Monoclonal, Humanized
TRX4antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients
This paper describes the pharmacological findings from a study where otelixizumab, an anti‐CD3ɛ mAb, was dosed in new onset Type… 
2016
2016
Subcutaneous Administration of Otelixizumab is Limited by Injection Site Reactions: Results of an Exploratory Study in Type 1 Diabetes Mellitus Patients.
Targeting CD3 antigens on human T lymphocytes with monoclonal antibodies has been shown to reduce the rate of decline of C… 
Review
2014
Review
2014
Prospects for therapeutic tolerance in humans
Purpose of reviewTo provide an overview of recent advances and future possibilities for therapeutic tolerance. Recent… 
2014
2014
Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 Diabetes
2013
2013
The Compelling Case for Anti-CD3 in Type 1 Diabetes
Immunotherapy trials in recent-onset type 1 diabetes (T1D) have had mixed results, with some therapies—anti-CD3 monoclonal… 
2013
2013
Virtual sensors for semiconductor manufacturing: A nonparametric approach - Exploiting information theoretic learning and Kernel machines
In this paper, a novel learning methodology is presented and discussed with reference to the application of virtual sensors in… 
2011
2011
Preservation of recall immunity in anti‐CD3‐treated recent onset type 1 diabetes patients
The safety of any immune modulating agent in type 1 diabetes mellitus (T1DM) involves its selectivity on autoimmunity and its… 
2010
2010
Molecule of the month. Otelixizumab.
2010
2010
Fasting and stimulated C-peptide at aseline in DEFEND-1, a phase 3 study of otelixizumab in new onset type 1 diabetes
2009
2009
Otelixizumab – dose regimen optimization of a chimeric/humanized aglycosylated anti-CD3 monoclonal antibody (MAb) in adult subjects with type 1 diabetes mellitus (T1DM)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)